Life sciences trade association BioNJ has announced the election of its 2025 Officers and Board Members in concert with BioNJ ...

With pharmaceutical companies banking on bacterial genomics to deliver novel targets for future antibiotics, several smaller companies are testing completely new ... Bristol Myers Squibb ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat.

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in ...

Core to its strategy, Bristol Myers Squibb actively invests in the development of new molecular entities, alongside strategically acquiring companies to amplify its R&D capabilities. This approach ...

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.70 per share a year ago.

Shares in Bristol-Myers Squibb traded about 2.7% lower Thursday after the drug maker gave 2025 guidance that undershot expectations. Bristol expects sales of about $45.5 billion in 2025 ...